Vir Biotechnology Inc. (VIR) Announces New Clinical Data From its Broad Hepatitis B Program
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 12/7/2023
- Wall St ends lower as investors weigh fresh employment data
- U.S. private employers add 103,000 jobs in November - ADP
- Data storage group MongoDB delivers upbeat guidance after Q3 results top estimates
- Stocks slip, 10-year Treasury yield falls as rate cut timing weighed
- A major Wall Street bank is out with S&P 500 forecast for 2024
- Mullen Automotive, Inc (MULN) Files Landmark Federal Spoofing Lawsuit to Combat Artificially Deflated Stock Prices
- Crude Inventory Data Shows Draw of 4.6 Million Barrels Last Week
- Analysis-Stock-hungry volatility funds, ‘gamma-heavy' options dealers could buoy US equities
- Nikola (NKLA) Announces Proposed Offerings of Common Stock and Convertible Senior Notes
- Palantir (PLTR) falls as co-founder Cohen sells nearly $13 million in stock
- After-hours movers: Cerevel surges on takeover, Chewy falls following results
- Midday movers: MongoDB, Citigroup, and more
- After-hours movers: SentinelOne up on earnings, MongoDB sees 'sell the news' reaction
- Midday movers: CVS Health, Apple, and more
- After-hours movers: GitLab surges on earnings, EyePoint adds to intra-day gains
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program
June 25, 2022 7:00 AM EDT Results from ongoing trials of VIR-2218 and VIR-3434 presented at the International
Liver Congress (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signals
Company expects to dose first patient in Part B of the Phase 2 MARCH trial by the end of June
SAN FRANCISCO, June 25, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B virus (HBV) clinical trial program, including results from an ongoing Phase 2 clinical trial of VIR-2218, results from an ongoing Phase 1 clinical trial of... More
